Growing attention is being given to the public health dimensions of perinatal mood and anxiety disorders (PMADs). Previously, we have reviewed studies looking at the prevalence of screening for PMADs and disparities therein and [...]
While depression is relatively common in pregnancy and we have data to support the reproductive safety of many different antidepressants, many women are reluctant to use antidepressant medications during pregnancy. Because untreated depression in [...]
While many women with postpartum depression (PPD) have had previous episodes of major depression and will go on to have other episodes of depression outside of the postpartum period, many have questioned whether postpartum depression [...]
The American College of Obstetricians and Gynecologists (ACOG) now recommends screening for perinatal depression and anxiety, stating that “clinicians screen patients at least once during the perinatal period for depression and anxiety symptoms using a [...]
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can modulate [...]
Previous research has shown that higher levels of depressive symptoms during pregnancy may be associated with lower levels of maternal-fetal attachment (MFA). Other studies have indicated that poor MFA is a significant predictor of worse [...]
A recently published article in the American Journal of Public Health has attributed a substantial financial cost to untreated perinatal mood and anxiety disorders among mothers. The study, conducted by researchers with the think [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the practice of reproductive psychiatry amidst the COVID-19 pandemic with Ob.Gyn News on [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
ACOG recommends that clinicians screen women at least once during the perinatal period for anxiety symptoms.
